Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide, characterized by accumulation of fat in the liver cells in people who drink little to no alcohol. Its prevalence is escalating, in tandem with the global rise in obesity and type 2 diabetes, making it a significant concern for healthcare providers.
Prevention strategies primarily revolve around lifestyle modifications. Encouraging patients to adopt a balanced diet, increase physical activity, and achieve a healthy body weight can significantly reduce the risk of developing NAFLD. Regular screening for metabolic risk factors such as hyperlipidemia, hypertension, and diabetes is also crucial in early detection and prevention.
Diagnosis of NAFLD involves a combination of medical history, physical examination, and laboratory tests. Imaging techniques such as ultrasound, CT, and MRI can be used to detect fatty liver, while liver biopsy remains the gold standard for diagnosing and staging NAFLD. Non-invasive tests, including transient elastography and serum biomarkers, are emerging as promising tools for diagnosing and monitoring disease progression.
Currently, there is no approved pharmacological therapy for NAFLD. The mainstay of treatment is lifestyle modification aimed at weight loss. In patients with NASH, vitamin E and pioglitazone have shown benefits. For advanced disease, liver transplantation may be considered. Ongoing research is focused on developing targeted therapies to address the underlying pathophysiology of NAFLD.
NAFLD is a growing health concern that necessitates proactive prevention, early detection, and effective management strategies. Healthcare professionals play a pivotal role in this endeavor. Keeping abreast of the latest research and advances in the field will ensure optimal patient care and outcomes in managing this complex disease.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation